BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9478	Companies
185484	Keywords
117839	Articles
99329	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 10/09/2025 at 09:05, 1 month 27 days ago

BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
BioNxt Solutions Inc. completes Track One priority patent filing with USPTO for sublingual thin-film cladribine formulation (BNT23001) targeting MS & other autoimmune diseases. Strategic move to strengthen IP position & advance regulatory approvals

BioNxt Solutions Inc. Multiple Sclerosis Patent Filing Sublingual Thin-Film Cladribine Formulation
BRIEF

published on 10/02/2025 at 09:10, 2 months 3 days ago

BioNxt développe une plateforme d'administration ciblée de médicaments de chimiothérapie

Biopharmaceutique Solutions BioNxt Administration De Médicaments Chimiothérapie Ciblée Avancées De La Recherche
BRIEF

published on 10/02/2025 at 09:10, 2 months 3 days ago

BioNxt Advances Targeted Chemotherapy Drug Delivery Platform

Biopharmaceutical Drug Delivery Research Advancements BioNxt Solutions Targeted Chemotherapy
PRESS RELEASE

published on 10/02/2025 at 09:05, 2 months 3 days ago

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
BioNxt Solutions Inc. reports significant advancement in targeted chemotherapy delivery platform and upcoming definitive agreement. Proprietary technology aims at 10-fold increase in therapeutic effect while safeguarding healthy cells

BioNxt Solutions Inc. Oncology Treatments Chemotherapy Delivery Platform Targeted Drug Delivery System Therapeutic Effect
BRIEF

published on 09/29/2025 at 09:10, 2 months 6 days ago

BioNxt Advances Cladribine Sublingual Drug Development for Multiple Sclerosis

Drug Development Multiple Sclerosis Cladribine Bioavailability Sublingual
BRIEF

published on 09/29/2025 at 09:10, 2 months 6 days ago

BioNxt fait progresser le développement d'un médicament sublingual à base de cladribine pour le traitement de la sclérose en plaques

Sclérose En Plaques Cladribine Développement De Médicaments Biodisponibilité Sublingual
PRESS RELEASE

published on 09/29/2025 at 09:05, 2 months 6 days ago

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
BioNxt Solutions provides update on Cladribine sublingual thin-film drug reformulation program, targeting treatment of multiple sclerosis with improved bioavailability and patient adherence

Multiple Sclerosis Cladribine Neurological Disorders BioNxt Solutions Drug Delivery Technologies
BRIEF

published on 09/20/2025 at 03:50, 2 months 15 days ago

BioNxt Solutions Completes Shares for Debt Settlement

Common Shares Debt Settlement Debt Agreement Canadian Securities BioNxt Solutions
BRIEF

published on 09/20/2025 at 03:50, 2 months 15 days ago

BioNxt Solutions lève des actions pour régler sa dette

Actions Ordinaires Règlement De La Dette Solutions BioNxt Valeurs Mobilières Canadiennes Accord De Dette
PRESS RELEASE

published on 09/20/2025 at 03:45, 2 months 15 days ago

BioNxt Solutions Announces Closing of Shares for Debt Settlement
BioNxt Solutions Inc. announces successful debt settlement with creditor, issuing common shares and making cash payment. Company focuses on bioscience innovation and drug delivery technologies

Common Shares Debt Settlement BioNxt Solutions Inc. Drug Delivery Technologies Bioscience Innovation

Accesswire

Published on 12/05/2025 at 15:35, 7 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 17 minutes ago

Usha Resources Provides Corporate Updates
Published on 12/05/2025 at 15:00, 42 minutes ago

Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 42 minutes ago

Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 42 minutes ago

Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 15:38, 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Published on 12/05/2025 at 15:36, 5 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
Published on 12/05/2025 at 15:35, 6 minutes ago

Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/05/2025 at 15:33, 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/05/2025 at 15:32, 9 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Alphawave IP Group plc

Les Echos

Published on 12/05/2025 at 15:10, 31 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 31 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 1 hour 43 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 6 hours 57 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 6 hours 57 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry

View all LES ECHOS COMFI WIRE